| In partnership with |  |
| Good day, 360! | Here are our top investing ideas today. And don't forget to join us in Market Masters - the hottest trading room around π₯. Be the best prepared trader on the Street! | | FOCUS LISTπ | TNXP - Up over 50% in the pre-market after presenting data on the potential Mpox Vaccine TNX-801 in "Using Synthetic Biology to Battle Mpox" talk at Immunology Symposium at the University of Alberta | SMMT - Up over 30% in pre after article published on BioPharma Dive stating Summit's lung cancer drug showed 'striking' benefit over Merck & Co.'s Keytruda. | TERN - Up over 25% in pre after announcing positive Phase 1 clinical trial results with TER-601 once-daily oral GLP-1R agonist for the treatment of obesity | | | | HOTLISTπ₯ | TNXP - Up over 50% in the pre-market after presenting data on the potential Mpox Vaccine TNX-801 in "Using Synthetic Biology to Battle Mpox" talk at Immunology Symposium at the University of Alberta | Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company that focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. | In the pre-market this morning, the company announced that it had presented data on the potential Mpox Vaccine TNX-801 in "Using Synthetic Biology to Battle Mpox" talk at Immunology Symposium at the University of Alberta | Highlights include: | TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine | New data show improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues even at high doses | Tonix's synthetic horsepox vaccine platform has been selected by NIH's Project NextGen for clinical testing | The stock traded up over 50% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $0.26. | Beyond that $0.32, $0.40, $0.45 and $0.50 come into play. | Below $0.26, targets to the downside are $0.24, $0.22, $0.2057, $0.20, $0.18 and then a gap fill at $0.1425 come into play. | | SMMT - Up over 30% in pre after article published on BioPharma Dive stating Summit's lung cancer drug showed 'striking' benefit over Merck & Co.'s Keytruda. | Summit Therapeutics Inc. (SMMT) is a biopharmaceutical company that focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. | Over the weekend, an article was published on BioPharma Dive stating Summit's lung cancer drug showed 'striking' benefit over Merck & Co.'s Keytruda. | Data showed Summit's drug held tumors at bay for a median of just over 11 months, compared to almost six months for those given Keytruda. The 5.3-month difference in progression-free survival equated to a statistically significant 49% reduction in the risk of cancer progression or death. | The stock traded up over 30% in reaction to the article and results. | | The $15.50 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $16, $17, $18, $19 and then the pre-market high at $19.95. | Below $15.50, targets to the downside are $14, $12.50, $11.50, $10.50, $9.50, $8.50 and then a gap fill at $7.81. | | TERN - Up over 25% in pre after announcing positive Phase 1 clinical trial results with TER-601 once-daily oral GLP-1R agonist for the treatment of obesity | Terns Pharmaceuticals Inc. (TERN) is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. | In the pre-market this morning, the company announced positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight. | Highlights include: | Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) | Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration | Distinct drug properties support potential to be a leading GLP-1R agonist | Plans to initiate Phase 2 clinical trial in 2025 | The stock traded up over 25% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $11.10. | Beyond that, $12, $13 and $14 come into play. | Below $11.10, targets to the downside are $10.50, $10, $9.50, $9. $8.50, $8 and then a gap fill at $7.81. | | MARKET NEWS π° | | P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
